• 11780 Citations
  • 38 h-Index
1973 …2019
If you made any changes in Pure these will be visible here soon.

Research Output 1973 2019

  • 11780 Citations
  • 38 h-Index
  • 218 Article
  • 2 Chapter
  • 1 Editorial
Filter
Article
2019
12 Citations (Scopus)

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Láng, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno-Aspitia, A., Piccart, M. & 2 others, Gelber, R. D. & de Azambuja, E., Jan 1 2019, In : Journal of the National Cancer Institute. 111, 1, p. 86-94 9 p.

Research output: Contribution to journalArticle

Amenorrhea
Breast Neoplasms
Survival
Hormones
Therapeutics

Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

Huober, J., Holmes, E., Baselga, J., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Láng, I., Smith, I., Boyle, F., Xu, B., Lecocq, C., Wildiers, H., Jouannaud, C., Hackman, J., Dasappa, L., Ciruelos, E., Toral Pena, J. C., Adamchuk, H., Hickish, T. & 5 others, de la Pena, L., Jackisch, C., Gelber, R. D., Piccart-Gebhart, M. & Di Cosimo, S., Sep 1 2019, In : European Journal of Cancer. 118, p. 169-177 9 p.

Research output: Contribution to journalArticle

Phase III Clinical Trials
Disease-Free Survival
Outcome Assessment (Health Care)
Breast Neoplasms
Survival
2018
21 Citations (Scopus)

Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial

Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Láng, I., Baena-Cañada, J. M., Thürlimann, B., Mamounas, E. P., Geyer, C. E., Gelber, S., Coates, A. S., Gelber, R. D., Rastogi, P., Regan, M. M., Wolmark, N. & Aebi, S., Apr 10 2018, In : Journal of Clinical Oncology. 36, 11, p. 1073-1079 7 p.

Research output: Contribution to journalArticle

Estrogen Receptors
Breast Neoplasms
Recurrence
Drug Therapy
Disease-Free Survival
Stomach Neoplasms
Fluorescence In Situ Hybridization
Placebos
Fluorescence
Immunohistochemistry
1 Citation (Scopus)

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

Munzone, E., Gray, K. P., Fumagalli, C., Guerini-Rocco, E., Láng, I., Ruhstaller, T., Gianni, L., Kammler, R., Viale, G., Di Leo, A., Coates, A. S., Gelber, R. D., Regan, M. M., Goldhirsch, A., Barberis, M. & Colleoni, M., Mar 27 2018, (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-10 10 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Breast Neoplasms
Mutation
Recurrence
Genes
2 Citations (Scopus)

Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer

Rubovszky, G., Budai, B., Ganofszky, E., Horváth, Z., Juhos, É., Madaras, B., Nagy, T., Szabó, E., Pintér, T., Tóth, E., Nagy, P., Láng, I. & Hitre, E., Apr 1 2018, In : Pathology and Oncology Research. 24, 2, p. 237-244 8 p.

Research output: Contribution to journalArticle

Biliary Tract Neoplasms
Exanthema
Survival
gemcitabine
Blood Platelets
2017
251 Citations (Scopus)

Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M. & Baselga, J., Jul 13 2017, In : New England Journal of Medicine. 377, 2, p. 122-131 10 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Placebos
Disease-Free Survival
Confidence Intervals
Adjuvant Chemotherapy
27 Citations (Scopus)

Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study

Borgquist, S., Giobbie-Hurder, A., Ahern, T. P., Garber, J. E., Colleoni, M., Láng, I., Debled, M., Ejlertsen, B., Von Moos, R., Smith, I., Coates, A. S., Goldhirsch, A., Rabaglio, M., Price, K. N., Gelber, R. D., Regan, M. M. & Thürlimann, B., Apr 10 2017, In : Journal of Clinical Oncology. 35, 11, p. 1179-1188 10 p.

Research output: Contribution to journalArticle

Breast
Cholesterol
Breast Neoplasms
letrozole
Tamoxifen
10 Citations (Scopus)

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

On behalf of CALOR trial investigators, Feb 1 2017, In : Annals of Surgical Oncology. 24, 2, p. 398-406 9 p.

Research output: Contribution to journalArticle

Recurrence
Segmental Mastectomy
Mastectomy
Thoracic Wall
Breast Neoplasms
6 Citations (Scopus)

predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

Duchnowska, R., Sperinde, J., Czartoryska-Arlukowicz, B., Myśliwiec, P., Winslow, J., Radecka, B., Petropoulos, C., Demlova, R., Orlikowska, M., Kowalczyk, A., Láng, I., Ziółkowska, B., Debska-Szmich, S., Merdalska, M., Grela-Wojewoda, A., Zawrocki, A., Biernat, W., Huang, W. & Jassem, J., Jan 1 2017, In : Oncotarget. 8, 61, p. 104149-104159 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Survival
Proteins
Paraffin
Protein-Tyrosine Kinases
2016
55 Citations (Scopus)

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT Trials

Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Price, K. N., Coates, A. S., Goldhirsch, A. & Gelber, R. D., Jul 1 2016, In : Journal of Clinical Oncology. 34, 19, p. 2221-2230 10 p.

Research output: Contribution to journalArticle

exemestane
Tamoxifen
Hormones
Breast Neoplasms
Therapeutics
154 Citations (Scopus)

Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Piccart-Gebhart, M., Holmes, E., Baselga, J., De Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., McCullough, A. E., Dolci, S., McFadden, E., Holmes, A. P., Tonghua, L., Eidtmann, H., Dinh, P., Di Cosimo, S., Harbeck, N., Tjulandin, S. & 15 others, Im, Y. H., Huang, C. S., Díeras, V., Hillman, D. W., Wolff, A. C., Jackisch, C., Láng, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Suter, T., Gelber, R. D. & Perez, E. A., Apr 1 2016, In : Journal of Clinical Oncology. 34, 10, p. 1034-1042 9 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Breast Neoplasms
Epidermal Growth Factor
Medical Futility
Therapeutics
22 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Zielinski, C., Láng, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Petruzelka, L., Eniu, A., Nisenbaum, B., Dank, M., Anghel, R., Messinger, D. & Brodowicz, T., Sep 1 2016, In : The Lancet Oncology. 17, 9, p. 1230-1239 10 p.

Research output: Contribution to journalArticle

Paclitaxel
Breast Neoplasms
Therapeutics
Survival
Capecitabine
63 Citations (Scopus)

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: Expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Finn, R. S., Crown, J. P., Ettl, J., Schmidt, M., Bondarenko, I. M., Láng, I., Pintér, T., Boer, K., Patel, R., Randolph, S., Kim, S. T., Huang, X., Schnell, P., Nadanaciva, S., Bartlett, C. H. & Slamon, D. J., Jun 28 2016, In : Breast Cancer Research. 18, 1, 67.

Research output: Contribution to journalArticle

letrozole
Estrogen Receptors
Breast Neoplasms
Neutropenia
Safety
6 Citations (Scopus)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients

For the Central and East European Oncology Group (CEEOG), Jan 1 2016, In : Oncotarget. 7, 1, p. 550-564 15 p.

Research output: Contribution to journalArticle

AMP-Activated Protein Kinases
Cyclin E
Breast Neoplasms
70-kDa Ribosomal Protein S6 Kinases
Mitogen-Activated Protein Kinases
12 Citations (Scopus)

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Bell, T., Crown, J. P., Láng, I., Bhattacharyya, H., Zanotti, G., Randolph, S., Kim, S., Huang, X., Huang Bartlett, C., Finn, R. S. & Slamon, D., May 3 2016, In : Current Medical Research and Opinion. 32, 5, p. 959-965 7 p.

Research output: Contribution to journalArticle

letrozole
Estrogen Receptors
Breast Neoplasms
Pain
Therapeutics
9 Citations (Scopus)

Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial

Sonnenblick, A., De Azambuja, E., Agbor-Tarh, D., Bradbury, I., Campbell, C., Huang, Y., Dueck, A. C., Pritchard, K. I., Wolff, A. C., Jackisch, C., Láng, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Perez, E. A., Piccart, M. & Azim, H. A., 2016, In : Journal of the National Cancer Institute. 108, 8, djw037.

Research output: Contribution to journalArticle

Exanthema
Breast Neoplasms
Confidence Intervals
Survival
lapatinib
32 Citations (Scopus)

Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00

Colleoni, M., Gray, K. P., Gelber, S., Láng, I., Thürlimann, B., Gianni, L., Abdi, E. A., Gomez, H. L., Linderholm, B. K., Puglisi, F., Tondini, C., Kralidis, E., Eniu, A., Cagossi, K., Rauch, D., Chirgwin, J., Gelber, R. D., Regan, M. M., Coates, A. S., Price, K. N. & 2 others, Viale, G. & Goldhirsch, A., Oct 1 2016, In : Journal of Clinical Oncology. 34, 28, p. 3400-3408 9 p.

Research output: Contribution to journalArticle

Methotrexate
Cyclophosphamide
Maintenance
Hormones
Breast Neoplasms
4 Citations (Scopus)

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: Results of the CECOG LaVie trial

Thallinger, C., Láng, I., Kuhar, C. G., Bartsch, R., Singer, C. F., Petruzelka, L., Melichar, B., Knittelfelder, R., Brodowicz, T. & Zielinski, C., Feb 18 2016, (Accepted/In press) In : BMC Cancer.

Research output: Contribution to journalArticle

Disease Progression
Breast Neoplasms
Safety
Disease-Free Survival
lapatinib
19 Citations (Scopus)

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Jerusalem, G., Mariani, G., Ciruelos, E. M., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Láng, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S. & Conte, P., Sep 1 2016, In : Annals of Oncology. 27, 9, p. 1719-1725 7 p., mdw249.

Research output: Contribution to journalArticle

exemestane
Compassionate Use Trials
Aromatase Inhibitors
Multicenter Studies
Hormones
57 Citations (Scopus)

Treatment adherence and its impact on Disease-Free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence

Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., Forbes, J. F., Neven, P., Láng, I., Colleoni, M. & Thürlimann, B., Jul 20 2016, In : Journal of Clinical Oncology. 34, 21, p. 2452-2459 8 p.

Research output: Contribution to journalArticle

letrozole
Tamoxifen
Disease-Free Survival
Breast
Proportional Hazards Models
37 Citations (Scopus)

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., Láng, I., Ruhstaller, T., Gianni, L., Goldhirsch, A., Kammler, R., Price, K. N., Cancello, G., Munzone, E., Gelber, R. D., Regan, M. M. & Colleoni, M., Jul 1 2016, In : Breast Cancer Research and Treatment. 158, 2, p. 323-331 9 p.

Research output: Contribution to journalArticle

Maintenance Chemotherapy
Triple Negative Breast Neoplasms
Tumor-Infiltrating Lymphocytes
Phase III Clinical Trials
Methotrexate
40 Citations (Scopus)

Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

Bellet, M., Gray, K. P., Francis, P. A., Láng, I., Ciruelos, E., Lluch, A., Climent, M. A., Catalán, G., Avella, A., Bohn, U., González-Martin, A., Ferrer, R., Catalán, R., Azaro, A., Rajasekaran, A., Morales, J., Vázquez, J., Fleming, G. F., Price, K. N. & Regan, M. M., May 10 2016, In : Journal of Clinical Oncology. 34, 14, p. 1584-1593 10 p.

Research output: Contribution to journalArticle

exemestane
Triptorelin Pamoate
Tamoxifen
Estrogens
Hormones
2015
285 Citations (Scopus)

Adjuvant ovarian suppression in premenopausal breast cancer

Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., Martino, S., Davidson, N. E., Geyer, C. E., Walley, B. A., Coleman, R., Kerbrat, P., Buchholz, S., Ingle, J. N., Winer, E. P. M., Rabaglio-Poretti, M. & 9 others, Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Colleoni, M., Viale, G., Coates, A. S., Goldhirsch, A. & Gelber, R. D., Jan 1 2015, In : New England Journal of Medicine. 372, 5, p. 436-446 11 p.

Research output: Contribution to journalArticle

Tamoxifen
Breast Neoplasms
exemestane
Recurrence
Confidence Intervals
7 Citations (Scopus)

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

Zielinski, C., Láng, I., Beslija, S., Kahán, Z., Inbar, M. J., Stemmer, S. M., Anghel, R., Vrbanec, D., Messinger, D. & Brodowicz, T., Dec 10 2015, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journalArticle

Breast Neoplasms
Bevacizumab
Capecitabine
Paclitaxel
Disease-Free Survival
Ductal Carcinoma
Estrone
Progesterone Receptors
Breast Neoplasms
Estrogen Receptors
803 Citations (Scopus)

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study

Finn, R. S., Crown, J. P., Láng, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pintér, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C., Huang, X., Kim, S. T., Randolph, S. & Slamon, D. J., 2015, In : The Lancet Oncology. 16, 1, p. 25-35 11 p.

Research output: Contribution to journalArticle

letrozole
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
Estrogen Receptors
Breast Neoplasms
2014
278 Citations (Scopus)

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., Ciruelos, E., Stearns, V., Bonnefoi, H. R., Martino, S., Geyer, C. E., Pinotti, G., Puglisi, F., Crivellari, D., Ruhstaller, T., Winer, E. P. & 13 others, Rabaglio-Poretti, M., Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Bernhard, J., Luo, W., Ribi, K., Viale, G., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Francis, P. A., 2014, In : New England Journal of Medicine. 371, 2, p. 107-118 12 p.

Research output: Contribution to journalArticle

exemestane
Tamoxifen
Aromatase Inhibitors
Breast Neoplasms
Triptorelin Pamoate
87 Citations (Scopus)

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., Villanueva, C., Romieu, G., Láng, I., Ciruelos, E., De Laurentiis, M., Veyret, C., de Ducla, S., Freudensprung, U., Srock, S. & Gligorov, J., Oct 1 2014, In : The Lancet Oncology. 15, 11, p. 1269-1278 10 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Drug Therapy
Disease-Free Survival
Therapeutics
Random Allocation
5 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor exemestane: A phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 346-347 2 p.

Research output: Contribution to journalArticle

exemestane
Aromatase Inhibitors
Hormones
Breast Neoplasms
Therapeutics
11 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor letrozole: A phase II trial in postmenopausalwomen evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 348-349 2 p.

Research output: Contribution to journalArticle

letrozole
Aromatase Inhibitors
Hormones
Breast Neoplasms
Aspartate Aminotransferases
105 Citations (Scopus)

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial

Aebi, S., Gelber, S., Anderson, S. J., Láng, I., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Cañada, J. M. B., Thürlimann, B., Murray, E., Mamounas, E. P., Geyer, C. E., Price, K. N., Coates, A. S., Gelber, R. D., Rastogi, P., Wolmark, N. & Wapnir, I. L., Feb 2014, In : The Lancet Oncology. 15, 2, p. 156-163 8 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Recurrence
Drug Therapy
Estrogen Receptors
Disease-Free Survival
266 Citations (Scopus)

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial

André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., Yap, Y. S., Papai, Z., Láng, I., Armstrong, A., Lerzo, G., White, M., Shen, K., Litton, J., Chen, D., Zhang, Y. & 3 others, Ali, S., Taran, T. & Gianni, L., 2014, In : The Lancet Oncology. 15, 6, p. 580-591 12 p.

Research output: Contribution to journalArticle

Placebos
Disease-Free Survival
Breast Neoplasms
Febrile Neutropenia
Stomatitis
210 Citations (Scopus)

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Láng, I., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Perez, E. A., Azim, H. A., Kim, S. B., Kuemmel, S., Huang, C. S., Vuylsteke, P., Hsieh, R. K. & 7 others, Gorbunova, V., Eniu, A., Dreosti, L., Tavartkiladze, N., Gelber, R. D., Eidtmann, H. & Baselga, J., Sep 1 2014, In : The Lancet Oncology. 15, 10, p. 1137-1146 10 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Survival
Disease-Free Survival
Paclitaxel
lapatinib
13 Citations (Scopus)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Brodowicz, T., Láng, I., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Petruzelka, L., Eniu, A., Anghel, R., Koynov, K., Vrbanec, D., Pienkowski, T., Melichar, B., Spanik, S., Ahlers, S., Messinger, D., Inbar, M. J. & Zielinski, C., Nov 25 2014, In : British Journal of Cancer. 111, 11, p. 2051-2057 7 p.

Research output: Contribution to journalArticle

Statistical Factor Analysis
Breast Neoplasms
Paclitaxel
Therapeutics
Triple Negative Breast Neoplasms
18 Citations (Scopus)

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

Huober, J., Cole, B. F., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D. & Thürlimann, B., Jan 2014, In : Breast Cancer Research and Treatment. 143, 1, p. 159-169 11 p.

Research output: Contribution to journalArticle

Myalgia
Arthralgia
Disease-Free Survival
Breast Neoplasms
Wrist
16 Citations (Scopus)

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial

Láng, I., Bell, R., Feng, F. Y., Lopez, R. I., Jassem, J., Semiglazov, V., Al-Sakaff, N., Heinzmann, D. & Chang, J., Feb 2014, In : Clinical Oncology. 26, 2, p. 81-89 9 p.

Research output: Contribution to journalArticle

Retreatment
Breast Neoplasms
Recurrence
Therapeutics
docetaxel
2013
3 Citations (Scopus)

A comparative analysis on the efficacy and safety of intaxelspi® and taxolspi® in advanced metastatic breast cancer

Láng, I., Rubovszky, G., Horváth, Z., Ganofszky, E., Szabó, E., Dank, M., Boer, K. & Hitre, E., Jun 1 2013, In : Journal of Clinical and Diagnostic Research. 7, 6, p. 1120-1124 5 p.

Research output: Contribution to journalArticle

Paclitaxel
Breast Neoplasms
Safety
Carboplatin
Doxorubicin
25 Citations (Scopus)

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a " standard chemotherapy regimen": The CASA randomized trial

Crivellari, D., Gray, K. P., Dellapasqua, S., Puglisi, F., Ribi, K., Price, K. N., Láng, I., Gianni, L., Spazzapan, S., Pinotti, G., Lüthi, J. M., Gelber, R. D., Regan, M. M., Colleoni, M., Castiglione-Gertsch, M., Maibach, R., Rabaglio, M., Coates, A. S. & Goldhirsch, A., Apr 2013, In : Breast. 22, 2, p. 130-137 8 p.

Research output: Contribution to journalArticle

Methotrexate
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Progesterone Receptors
16 Citations (Scopus)

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: The adjuvant lapatinib and/or trastuzumab treatment optimization experience

Metzger-Filho, O., de Azambuja, E., Bradbury, I., Saini, K. S., Bines, J., Simon, S. D., van Dooren, V., Aktan, G., Pritchard, K. I., Wolff, A. C., Smith, I., Jackisch, C., Láng, I., Untch, M., Boyle, F., Xu, B., Baselga, J., Perez, E. A. & Piccart-Gebhart, M., 2013, In : Oncologist. 18, 2, p. 134-140 7 p.

Research output: Contribution to journalArticle

Phase III Clinical Trials
Breast Neoplasms
Ethics Committees
Research Ethics Committees
Therapeutics
78 Citations (Scopus)

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

Martin, M., Bonneterre, J., Geyer, C. E., Ito, Y., Ro, J., Láng, I., Kim, S. B., Germa, C., Vermette, J., Wang, K., Wang, K. & Awada, A., Dec 2013, In : European Journal of Cancer. 49, 18, p. 3763-3772 10 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Disease-Free Survival
Capecitabine
lapatinib

Az epeúti carcinomák gyógyszeres kezelé sének lehetõségei. Múlt - Jelen - Jóvo

Gábor, R., Hitre, E. & Láng, I., 2013, In : Lege Artis Medicinae. 23, 5-6, p. 255-261 7 p.

Research output: Contribution to journalArticle

Biliary Tract Neoplasms
Bile Duct Neoplasms
Drug Therapy
Gallbladder Neoplasms
Therapeutics
295 Citations (Scopus)

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial

Cunningham, D., Láng, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D. & Saunders, M. P., Oct 2013, In : The Lancet Oncology. 14, 11, p. 1077-1085 9 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
oxaliplatin
irinotecan
Disease-Free Survival
Poisons
73 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: Interim efficacy results of the randomised, Open-label, Non-inferiority, Phase 3 TURANDOT trial

Láng, I., Brodowicz, T., Ryvo, L., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Messinger, D. & Zielinski, C., Feb 2013, In : The Lancet Oncology. 14, 2, p. 125-133 9 p.

Research output: Contribution to journalArticle

Paclitaxel
Breast Neoplasms
Therapeutics
Population
Capecitabine

Breast cancer treatment in Hungary - First step into molecular medicine

Láng, I., Feb 2013, In : Memo - Magazine of European Medical Oncology. 6, 1, p. 1-2 2 p.

Research output: Contribution to journalArticle

Molecular Medicine
Hungary
Breast Neoplasms
32 Citations (Scopus)

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study

Rubovszky, G., Láng, I., Ganofszky, E., Horváth, Z., Juhos, É., Nagy, T., Szabó, E., Szentirmay, Z., Budai, B. & Hitre, E., Dec 2013, In : European Journal of Cancer. 49, 18, p. 3806-3812 7 p.

Research output: Contribution to journalArticle

gemcitabine
Biliary Tract Neoplasms
Gallbladder Neoplasms
Drug Therapy
Survival
29 Citations (Scopus)
Adenoid Cystic Carcinoma
Platinum
Epidermal Growth Factor Receptor
Drug Therapy
Neoplasm Metastasis
65 Citations (Scopus)

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01)

Pestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Láng, I., Wardley, A., Lichinitser, M., Sanchez, R. I. L., Müller, V., Dodwell, D., Gelber, R. D., Piccart-Gebhart, M. J. & Cameron, D., Mar 2013, In : The Lancet Oncology. 14, 3, p. 244-248 5 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Recurrence
Disease-Free Survival
Observation
Trastuzumab
132 Citations (Scopus)
exemestane
Breast Neoplasms
Aromatase Inhibitors
Disease-Free Survival
letrozole
132 Citations (Scopus)

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - A randomized controlled phase III trial

Goss, P. E., Ingle, J. N., Pritchard, K. I., Ellis, M. J., Sledge, G. W., Budd, G. T., Rabaglio, M., Ansari, R. H., Johnson, D. B., Tozer, R., D'Souza, D. P., Chalchal, H., Spadafora, S., Stearns, V., Perez, E. A., Liedke, P. E. R., Láng, I., Elliott, C., Gelmon, K. A., Chapman, J. A. W. & 1 others, Shepherd, L. E., Apr 10 2013, In : Journal of Clinical Oncology. 31, 11, p. 1398-1404 7 p.

Research output: Contribution to journalArticle

exemestane
Breast Neoplasms
Aromatase Inhibitors
Disease-Free Survival
letrozole